Skip to main content
Erschienen in: Diabetologia 3/2006

01.03.2006 | Short communication

In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100

verfasst von: S. Das, M. Shahmanesh, M. Stolinski, F. Shojaee-Moradie, W. Jefferson, N. C. Jackson, M. Cobbold, P. Nightingale, A. M. Umpleby

Erschienen in: Diabetologia | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We hypothesised that loss of peripheral fat in HIV patients would result in decreased plasma adipocytokines, in particular adiponectin, and that this decrease would be associated with changes in VLDL, IDL and LDL apolipoprotein B kinetics.

Methods

Plasma adiponectin, leptin and other cytokines were measured in uninfected control subjects (n=12) and three HIV-positive groups comprising treatment-naïve patients (n=15) and patients on triple antiretroviral therapy containing protease inhibitors (PI, n=15) or non-nucleoside reverse transcriptase inhibitors (NNRTI, n=25). VLDL, IDL and LDL apolipoprotein B kinetics were measured with an infusion of [1−13C] leucine. Regional body fat was measured with a dual energy X-ray absorptiometry scan. Insulin resistance was calculated using homeostasis model assessment (HOMA).

Results

Adiponectin (median [interquartile range]) was reduced in the treatment-naive (5.4 μg/ml [4.7–8.5]), PI (5.0 μg/ml [3.3–6.4]) and NNRTI (5.0 μg/ml [3.1–6.7]) groups compared with controls (9.7 μg/ml [6.9–13.3]) (p<0.05). In all subjects adiponectin correlated positively with HDL-cholesterol levels, the VLDL, IDL and LDL apolipoprotein B fractional clearance rates, and with the limb fat:lean body mass ratio (all p<0.01). Adiponectin correlated negatively with plasma triglyceride levels and HOMA (p<0.001). In a linear regression model that included HOMA, adiponectin was an independent predictor of VLDL and HDL-cholesterol levels and the IDL fractional clearance rate. TNF was higher in treatment-naive and PI subjects, and soluble TNF receptor superfamily, members 1A and 1B (previously known as TNF receptors 1 and 2) was higher in PI patients than in control subjects (p<0.05).

Conclusions/interpretation

Adiponectin levels are significantly reduced in treated and untreated HIV patients and are predictive of VLDL and IDL apolipoprotein B fractional clearance rates. Adiponectin may have a direct effect on lipoprotein metabolism, which may be independent of insulin.
Literatur
1.
Zurück zum Zitat Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. (Review). Proc Nutr Soc 60:329–339PubMedCrossRef Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. (Review). Proc Nutr Soc 60:329–339PubMedCrossRef
2.
Zurück zum Zitat Schmitz M, Michl G, Walli R et al (2001) Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 26:225–235CrossRefPubMed Schmitz M, Michl G, Walli R et al (2001) Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 26:225–235CrossRefPubMed
3.
Zurück zum Zitat Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS (2003) Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88:627–636CrossRefPubMed Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS (2003) Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 88:627–636CrossRefPubMed
4.
Zurück zum Zitat Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMed
5.
Zurück zum Zitat Matsubara M, Maruoka S, Katayose S (2002) Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87:2764–2769CrossRefPubMed Matsubara M, Maruoka S, Katayose S (2002) Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87:2764–2769CrossRefPubMed
6.
Zurück zum Zitat Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH (2005) Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 54:795–802PubMedCrossRef Ng TW, Watts GF, Farvid MS, Chan DC, Barrett PH (2005) Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 54:795–802PubMedCrossRef
7.
Zurück zum Zitat Xu A, Yin S, Wong L, Chan KW, Lam KS (2004) Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145:487–494CrossRefPubMed Xu A, Yin S, Wong L, Chan KW, Lam KS (2004) Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145:487–494CrossRefPubMed
8.
Zurück zum Zitat Shahmanesh M, Das S, Stolinski M et al (2005) Antiretroviral treatment reduces VLDL and IDL apolipoprotein B fractional catabolic rate in HIV infected patients with mild dyslipidaemia J Clin Endocrinol Metab 90:755–760CrossRefPubMed Shahmanesh M, Das S, Stolinski M et al (2005) Antiretroviral treatment reduces VLDL and IDL apolipoprotein B fractional catabolic rate in HIV infected patients with mild dyslipidaemia J Clin Endocrinol Metab 90:755–760CrossRefPubMed
9.
Zurück zum Zitat Umpleby AM, Das S, Stolinski M et al (2005) LDL apolipoprotein B metabolism in treatment naïve HIV patients and patients on antiretroviral therapy. Antivir Ther 10:663–670PubMed Umpleby AM, Das S, Stolinski M et al (2005) LDL apolipoprotein B metabolism in treatment naïve HIV patients and patients on antiretroviral therapy. Antivir Ther 10:663–670PubMed
10.
Zurück zum Zitat Kannisto K, Sutinen J, Korsheninnikova E et al (2003) Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 17:1753–1762CrossRefPubMed Kannisto K, Sutinen J, Korsheninnikova E et al (2003) Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 17:1753–1762CrossRefPubMed
11.
Zurück zum Zitat Sutinen J, Hakkinen AM, Westerbacka J et al (2002) Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16:2183–2193CrossRefPubMed Sutinen J, Hakkinen AM, Westerbacka J et al (2002) Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16:2183–2193CrossRefPubMed
12.
Zurück zum Zitat Bugianesi E, Pagotto U, Manini R et al (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498–3504CrossRefPubMed Bugianesi E, Pagotto U, Manini R et al (2005) Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 90:3498–3504CrossRefPubMed
13.
Zurück zum Zitat Bastard JP, Caron M, Vidal H et al (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359:1026–1031CrossRefPubMed Bastard JP, Caron M, Vidal H et al (2002) Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359:1026–1031CrossRefPubMed
14.
Zurück zum Zitat von Eynatten M, Schneider JG, Humpert PM et al (2004) Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 27:2925–2929PubMedCrossRef von Eynatten M, Schneider JG, Humpert PM et al (2004) Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 27:2925–2929PubMedCrossRef
Metadaten
Titel
In treatment-naïve and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100
verfasst von
S. Das
M. Shahmanesh
M. Stolinski
F. Shojaee-Moradie
W. Jefferson
N. C. Jackson
M. Cobbold
P. Nightingale
A. M. Umpleby
Publikationsdatum
01.03.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 3/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0085-3

Weitere Artikel der Ausgabe 3/2006

Diabetologia 3/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.